MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Multiple system atrophy(MSA): Treatment"

  • 2023 International Congress

    Short-term effect of continuous positive airway pressure in MSA patients with sleep disordered breathing

    G. Lazzeri, M. Houot, M. Patout, F. Cormier, M. Vidailhet, JC. Corvol, I. Arnulf, D. Grabli, P. Dodet (Milan, Italy)

    Objective: SBD are frequent in MSA, mainly represented by inspiratory stridor, obstructive and central sleep apnea/hypopnea syndrome (SAS), or hypopneaimpacting the quality of sleep. A…
  • 2023 International Congress

    An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials

    R. Freeman, I. Biaggioni, L. Norcliffe-Kaufmann, T. Guerin, R. Vickery, L. Manzanares, V. Iodice, M. Rudzińska-Bar, M. Pellecchia, H. Kaufmann (Boston, USA)

    Objective: To present results in the subset of patients with multiple system atrophy (MSA) and relevant MSA subgroups from two ampreloxetine phase 3 trials for…
  • 2023 International Congress

    Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL

    A. Bernhardt, M. Oeller, I. Friedrich, E. Kocakavuk, E. Nachman, K. Peikert, M. Roderigo, A. Rossmann, T. Schröter, LO. Wilhelm, F. Gandor, J. Levin, A. Giese, A. Janzen, WH. Oertel (Munich, Germany)

    Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…
  • 2023 International Congress

    Use of levodopa-carbidopa intestinal gel to treat a patient with multiple system atrophy (MSA)

    A. Ferreira, S. Marques, A. Vieira, M. Coelho, G. Carneiro, M. Rodrigues (Braga, Portugal)

    Objective: To describe a case report on the use of Levodopa-carbidopa intestinal gel (LCIG) to treat non-motor symptoms in a patient with multiple system atrophy (MSA) Background: There is no…
  • 2023 International Congress

    UMSARS versus laryngoscopy-based assessment of dysphagia

    N. El Fassi, A. Pavy-Le-Traon, E. Mouchon, O. Rascol, W. Meissner, A. Foubert-Saumier, Y. Gallois, S. Tessier, F. Ory-Magne, V. Woizard, M. Fabbri (Toulouse, France)

    Objective: To compare the Unified Multiple System Atrophy Rating Scale (UMSARS)   part I-item 2 with an ear/nose/throat (ENT) expert physician assessment. Background: Early and severe…
  • 2022 International Congress

    Safety and Efficacy of Verdiperstat, a Novel Myeloperoxidase Inhibitor, in MSA

    I. Qureshi, V. Wirtz, L. Brady, J. Ellison, A. Ellenbogen, R. Freeman, G. Höglinger, H. Kaufmann, A. Lang, P. Low, W. Meissner, P. Millar Vernetti, H. Morris, J. Palma, S. Perlman, W. Poewe, J. Schmahmann, K. Seppi, W. Singer, S. Vernino, G. Wenning (New Haven, USA)

    Objective: To present results from M-STAR, a phase 3, randomized controlled trial evaluating the disease modifying effect of verdiperstat in participants with MSA. Background: MSA…
  • 2022 International Congress

    Focused ultrasound offers tremor relief in multiple system atrophy patients

    M. Nassar, A. Sinai, L. Shornikov, I. Erikh, M. Constantinescu, M. Zaaroor, I. Schlesinger (Haifa, Israel)

    Objective: To report on the efficacy and safety of MRI-guided focused ultrasound (FUS) VIM-thalamotomy in patients with multiple system atrophy (MSA). Background: FUS has established…
  • 2022 International Congress

    The shaky truth of a Movement Disorder Nurse pilot program in Rural Australia

    L. Bellizzi (Horsham, Australia)

    Objective: The conception of the Movement Disorder Nurse program began when the Australian Government and Fight Parkinson’s conducted a scoping evaluation of people living with…
  • 2022 International Congress

    It takes a village: An interdisciplinary care model for atypical Parkinsonism

    H. Glover, J. Shurer, M. Ivancic, M. Sklerov (Chapel Hill, USA)

    Objective: To describe one interdisciplinary clinic designed to offer comprehensive care to patients with atypical parkinsonism syndromes, and to share the lessons learned which may…
  • MDS Virtual Congress 2021

    Cerebellar tDCS for multiple system atrophy cerebellar: Double blinded, randomized, sham-control, cross-over study

    JH. Ahn, J. Song, I. Choi, DY. Lee, JW. Cho, WH. Chang, J. Youn (Seoul, Republic of Korea)

    Objective: The aim of study is to investigate an effect of a transcranial direct current stimulation (tDCS) on the primary motor cortex (M1) and cerebellum…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley